Neoadjuvant therapy in renal cell carcinoma with tumor thrombus : A systematic review and meta-analysis
Copyright © 2024 Elsevier B.V. All rights reserved..
To evaluate the efficacy, feasibility and safety of neoadjuvant therapy (NAT) for renal cell carcinoma with tumor thrombus (RCC-TT) in terms of response, perioperative and oncological outcomes, and compare the results between neoadjuvant and non-neoadjuvant groups. Overall, 29 single-arm studies and 5 cohort studies were included. Of the 204 patients undergoing NAT, 16.2% were level I, 35.3% level II, 24.0% level III and 18.6% level IV thrombus. Most of patients underwent preoperative targeted therapy, immunotherapy-based combination therapy was applied in 5.4% patients. The total reduction rate of thrombus level was 29.4%. NAT is associated with a shorter operative time, less blood loss (p<0.05 for both). Rate of complications and oncological outcomes were similar between two groups. Overall, 32.1% (34/106) ≥ grade 3 adverse events occurred in patients undergoing NAT. Neoadjuvant therapy is safe and feasible with acceptable perioperative outcomes in RCC-TT.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:196 |
|---|---|
| Enthalten in: |
Critical reviews in oncology/hematology - 196(2024) vom: 10. Apr., Seite 104316 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Gu, Liangyou [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Journal Article |
|---|
| Anmerkungen: |
Date Completed 08.04.2024 Date Revised 08.04.2024 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.critrevonc.2024.104316 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM369223195 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM369223195 | ||
| 003 | DE-627 | ||
| 005 | 20240408232527.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240304s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.critrevonc.2024.104316 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1369.xml |
| 035 | |a (DE-627)NLM369223195 | ||
| 035 | |a (NLM)38432444 | ||
| 035 | |a (PII)S1040-8428(24)00059-3 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Gu, Liangyou |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Neoadjuvant therapy in renal cell carcinoma with tumor thrombus |b A systematic review and meta-analysis |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 08.04.2024 | ||
| 500 | |a Date Revised 08.04.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2024 Elsevier B.V. All rights reserved. | ||
| 520 | |a To evaluate the efficacy, feasibility and safety of neoadjuvant therapy (NAT) for renal cell carcinoma with tumor thrombus (RCC-TT) in terms of response, perioperative and oncological outcomes, and compare the results between neoadjuvant and non-neoadjuvant groups. Overall, 29 single-arm studies and 5 cohort studies were included. Of the 204 patients undergoing NAT, 16.2% were level I, 35.3% level II, 24.0% level III and 18.6% level IV thrombus. Most of patients underwent preoperative targeted therapy, immunotherapy-based combination therapy was applied in 5.4% patients. The total reduction rate of thrombus level was 29.4%. NAT is associated with a shorter operative time, less blood loss (p<0.05 for both). Rate of complications and oncological outcomes were similar between two groups. Overall, 32.1% (34/106) ≥ grade 3 adverse events occurred in patients undergoing NAT. Neoadjuvant therapy is safe and feasible with acceptable perioperative outcomes in RCC-TT | ||
| 650 | 4 | |a Meta-Analysis | |
| 650 | 4 | |a Systematic Review | |
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Review | |
| 650 | 4 | |a Neoadjuvant therapy | |
| 650 | 4 | |a Oncological outcomes | |
| 650 | 4 | |a Perioperative outcomes | |
| 650 | 4 | |a Renal cell carcinoma | |
| 650 | 4 | |a Response | |
| 650 | 4 | |a Tumor thrombus | |
| 700 | 1 | |a Peng, Cheng |e verfasserin |4 aut | |
| 700 | 1 | |a Li, Huaikang |e verfasserin |4 aut | |
| 700 | 1 | |a Jia, Tongyu |e verfasserin |4 aut | |
| 700 | 1 | |a Chen, Xinran |e verfasserin |4 aut | |
| 700 | 1 | |a Wang, Hanfeng |e verfasserin |4 aut | |
| 700 | 1 | |a Du, Songliang |e verfasserin |4 aut | |
| 700 | 1 | |a Tang, Lu |e verfasserin |4 aut | |
| 700 | 1 | |a Liang, Qiyang |e verfasserin |4 aut | |
| 700 | 1 | |a Wang, Baojun |e verfasserin |4 aut | |
| 700 | 1 | |a Ma, Xin |e verfasserin |4 aut | |
| 700 | 1 | |a Zhang, Xu |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Critical reviews in oncology/hematology |d 1996 |g 196(2024) vom: 10. Apr., Seite 104316 |w (DE-627)NLM012606006 |x 1879-0461 |7 nnns |
| 773 | 1 | 8 | |g volume:196 |g year:2024 |g day:10 |g month:04 |g pages:104316 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.critrevonc.2024.104316 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 196 |j 2024 |b 10 |c 04 |h 104316 | ||